Modulation of inflammatory and metastatic processes
申请人:Heise Carla
公开号:US20050239825A1
公开(公告)日:2005-10-27
Methods of using compounds having Structure I or the salts or tautomers of the compounds in the treatment of disorders relating to cell adhesion and metastatic processes are presented herein.
Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
申请人:Cai Shaopei
公开号:US20050209247A1
公开(公告)日:2005-09-22
A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R
1
-R
9
and R
12
-R
14
are as defined herein
PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES
申请人:Cai Shaopei
公开号:US20130018058A1
公开(公告)日:2013-01-17
A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R
1
-R
9
and R
12
-R
14
are as defined herein
Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties
申请人:Cai Shaopei
公开号:US20130338171A1
公开(公告)日:2013-12-19
A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R
1
-R
9
and R
12
-R
14
are as defined herein